Unbalanced AI funding and human resources
Warp Sciences has raised $215 million to build a lab that uses AI and robots to run chemical experiments. During the same period, American Express was reported to be cutting 5% of its workforce, and Colliers warned that a lack of AI talent could hinder growth in Europe. In a place where funding and expectations are high, a reshuffle of personnel and a shortage of personnel are occurring at the same time. What the articles we will read in this half-day have in common is the view that the difference between success and failure is less about how much money is invested in AI and more about how the investment goes through on-site verification and by whose hands it is run. Research in diagnosis, speech classification, and prediction also confronts readers with the differences between results under appropriate conditions and results in real environments.
Warp Sciences raises $215 million to build an AI-powered drug discovery lab (citybiz). According to BRIDGE, the company is a company that uses AI and robots to conduct chemical experiments for drug discovery, and the company raised funding through a Series A led by Lightspeed. At the Series A stage, more than $200 million was raised. The destination of the funds is also a point of interest. The aim is not only to develop software and models, but also to build labs to actually perform experiments and automate chemical experiments.
Another company, Pathos, an AI drug discovery company, raised $237 million at a valuation of $3 billion (STAT). Reuters reports that Pathos will partner with Bristol Myers and Tempus AI to advance drug development (Reuters). Here, the procurement amount and valuation value include the practical ties of a partnership with a major pharmaceutical company. The reason why funds are being raised is not just the promise of AI alone. It appears that evaluation will also include how it will be incorporated into the development process of pharmaceutical companies.
The total amount raised by the two companies comes to $452 million. This scale shows that expectations for drug discovery AI go beyond the superiority of algorithms and extend to investments in the entire business, including experimental equipment and partners. What readers should take away from these numbers is not the high valuation itself. The question is whether the funds are being used in the form of automated experimental setups or collaborations with big pharmaceutical companies.
